T. Rowe Price Associates’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-159,290
| Closed | -$478K | – | 2920 |
|
|
2023
Q3 | $478K | Sell |
159,290
-3,146
| -2% | -$9.44K | ﹤0.01% | 2120 |
|
|
2023
Q2 | $400K | Sell |
162,436
-16,004
| -9% | -$39.4K | ﹤0.01% | 2231 |
|
|
2023
Q1 | $404K | Sell |
178,440
-9,019
| -5% | -$20.4K | ﹤0.01% | 2197 |
|
|
2022
Q4 | $654K | Sell |
187,459
-9,097
| -5% | -$31.7K | ﹤0.01% | 2003 |
|
|
2022
Q3 | $7.28M | Buy |
196,556
+27,799
| +16% | +$1.03M | ﹤0.01% | 1123 |
|
|
2022
Q2 | $3.21M | Buy |
168,757
+11,192
| +7% | +$213K | ﹤0.01% | 1487 |
|
|
2022
Q1 | $4.25M | Buy |
+157,565
| New | +$4.25M | ﹤0.01% | 1489 |
|
|
2021
Q4 | – | Sell |
-8,057
| Closed | -$211K | – | 3027 |
|
|
2021
Q3 | $211K | Buy |
+8,057
| New | +$211K | ﹤0.01% | 2697 |
|
|
2020
Q1 | – | Sell |
-129,461
| Closed | -$5.05M | – | 2550 |
|
|
2019
Q4 | $5.05M | Buy |
+129,461
| New | +$5.05M | ﹤0.01% | 1392 |
|